Regeneron reports Q2 2026 results, cemdisiran filings accepted, fianlimab trial missesJul 30Quarterly updatecemdisiranfianlimab
Alnylam cuts 2026 TTR revenue outlook, advances Alzheimer's and rare disease pipelineJul 30Quarterly updateAlnylam Pharmaceuticals
Sign inSign in